First-Line Asthma Medication for Adults and Adolescents
The first-line medication for asthma control in adults and adolescents (≥12 years) is low-dose ICS-formoterol (budesonide-formoterol 160/4.5 mcg or beclometasone-formoterol 100/6 mcg) used as an anti-inflammatory reliever (AIR), taken as-needed only for patients with infrequent symptoms. 1
Preferred Treatment Approach: GINA Track 1
The 2026 GINA guidelines establish Track 1 as the preferred treatment regimen because it substantially reduces severe exacerbations, oral corticosteroid exposure, and urgent healthcare utilization compared to SABA-only or traditional ICS regimens. 1
Dosing Schedule by Treatment Step
For patients with infrequent symptoms (Step 1-2):
- Budesonide-formoterol 160/4.5 (200/6) mcg OR beclometasone-formoterol 100/6 mcg
- Dosing: 1 inhalation as needed only (AIR-only approach)
- Advise patients to seek medical care if >12 total inhalations needed in 24 hours 1
For patients requiring maintenance therapy (Step 3):
- Same medication formulations
- Dosing: 1 inhalation twice daily (or once daily) PLUS 1 inhalation as needed (MART approach)
- Maximum: 12 total inhalations per 24 hours 1
For more severe disease (Step 4-5):
- Same medication formulations
- Dosing: 2 inhalations twice daily PLUS 1 inhalation as needed (MART)
- Maximum: 12 total inhalations per 24 hours 1
Why This Approach Is Superior
The evidence supporting ICS-formoterol as first-line therapy is compelling:
- Reduces severe exacerbations by ≥60% compared to SABA-only treatment in mild asthma 2
- Lower maintenance ICS dose required compared to traditional regimens with separate SABA relievers 1
- Single inhaler, single dose, single device across all treatment steps, which reduces confusion, improves adherence, and minimizes inhaler technique errors 1
- Benefits are independent of inflammatory phenotype, as both the ICS and formoterol components contribute to exacerbation reduction 1
Critical Implementation Points
No other ICS-LABA combination can be used as a reliever - only formoterol-containing combinations have the rapid onset needed for symptom relief. 1
Patients must understand the dual role: The same inhaler provides both daily maintenance (if prescribed) and immediate symptom relief. They should carry it at all times and use 1 inhalation whenever symptoms occur, waiting a few minutes before taking a second if needed. 1
Proper inhaler technique is essential: pMDIs must be shaken immediately before each actuation to avoid substantial over- or underdosing. 1
Alternative Track 2 (When Track 1 Unavailable)
If ICS-formoterol combinations are not available or affordable, Track 2 uses:
- Separate daily ICS (low-dose at Step 2, medium-to-high dose at Steps 3-5)
- Plus as-needed SABA for symptom relief
- This requires two different inhalers and potentially two different devices, increasing complexity 1
Common Pitfalls to Avoid
Never prescribe SABA alone - all adults and adolescents with asthma should receive ICS-containing medication, as SABA-only treatment increases mortality risk and exacerbation frequency. 3, 2
Don't confuse formoterol with other LABAs - salmeterol and other long-acting beta-agonists cannot be used as relievers due to slower onset of action. 1
Avoid maintenance oral corticosteroids except as absolute last resort in severe asthma after optimizing all other therapies including biologics. 1
The Chinese guidelines 4 align with GINA recommendations, confirming that ICS-LABA combinations demonstrate synergistic anti-inflammatory effects and are particularly recommended for moderate-to-severe asthma, achieving efficacy equivalent to or better than doubling the ICS dose alone.